Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AARD
Strong SellSinkerAardvark Therapeutics, Inc. · Healthcare · United States · $127M · Avg Vol: $656K/d
COMPANY DESCRIPTION
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for metabolic and inflammatory diseases. The company's lead program targets bitter taste receptors (TAS2R) to regulate appetite and metabolic function, offering a unique mechanism of action in the obesity space. Its competitive moat is supported by a proprietary drug discovery platform and a robust intellectual property portfolio.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.39 | -0.56 | -0.96 | -2.93 | — | -3.22 | -3.17 | -2.78 | — |
| Shares | 21.4M | 21.4M | 21.7M | 21.8M | +2.0% | 21.9M | — | — | — |
| Debt | 0.3M | 0.2M | 0.8M | 0.4M | 19.0% | 0.7M | — | — | — |
| Equity | -27.9M | -34.8M | -54.6M | 106.6M | — | — | — | — | — |
| Op CF | -10.5M | -5.8M | -18.1M | -54.2M | — | -69.4M | — | — | — |
| Inv CF | -1.0M | 0 | -12.0M | -49.7M | — | — | — | — | — |
| Fin CF | 0.2M | 0 | 82.0M | 89.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AARD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc.(you) | $127M | 18 | Strong Sell |
| VTVT | vTv Therapeutics Inc. | $128M | 18 | Strong Sell |
| BMEA | Biomea Fusion, Inc. | $125M | 16 | Strong Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 22 | Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 11 | Strong Sell |
| GUTS | Fractyl Health, Inc. | $105M | 14 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 12 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%